证券之星消息，截至2025年10月30日收盘，英科医疗(300677)报收于39.33元，上涨1.08%，换手率 4.03%，成交量18.77万手，成交额7.48亿元。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-30 | 39.33 | 1.08% | 1129.32万 | 1.51% | 2751.05万 | 3.68% | -3880.37万 | -5.18% | | 2025-10-29 | 38.91 | 0.91% | -2030.13万 | -3.43% | -3758.70万 | -6.36% | 5788.82万 | 9.79% | | 2025-10-28 | 38.56 | -8.58% | -7390.07万 | -5.70% | 857.52万 | 0.66% | 6532.55万 | 5.03% | | 2025-10-27 | 42.18 | 5.13% | 4092.23 ...

Core Viewpoint - As of October 29, 2025, Yingke Medical (300677) closed at 38.91 yuan, with a slight increase of 0.91% and a trading volume of 15.34 million shares, amounting to a total transaction value of 5.91 billion yuan [1] Financial Performance - For the first three quarters of 2025, Yingke Medical reported a main business revenue of 7.425 billion yuan, a year-on-year increase of 4.6%, and a net profit attributable to shareholders of 924 million yuan, up 34.47% year-on-year [3] - The third quarter of 2025 saw a single-quarter main business revenue of 2.511 billion yuan, a decrease of 2.9% year-on-year, while the single-quarter net profit attributable to shareholders was 214 million yuan, an increase of 113.04% year-on-year [3] - The company’s gross profit margin stands at 23.7%, with a net profit margin of 12.82% [3] Market Position - Yingke Medical has a total market capitalization of 25.478 billion yuan, ranking 8th in the medical device industry [3] - The company’s price-to-earnings ratio (P/E) is 20.67, significantly lower than the industry average of 59.7, ranking 11th in the industry [3] - The company’s return on equity (ROE) is 5.19%, which is higher than the industry average of 2.88%, ranking 46th in the industry [3] Capital Flow Analysis - On October 29, 2025, the net outflow of main funds was 20.3013 million yuan, accounting for 3.43% of the total transaction value, while retail investors saw a net inflow of 57.8882 million yuan, representing 9.79% of the total transaction value [1][2] - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net outflows from main and speculative funds on several days [2]

Company Overview - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009. The company was listed on July 21, 2017. Its main business includes three segments: personal protection (91.47%), rehabilitation care (4.75%), and other products (3.77%) [1][2]. Financial Performance - As of June 30, 2025, Yingke Medical achieved a revenue of 4.913 billion yuan, representing a year-on-year growth of 8.90%. The net profit attributable to shareholders was 710 million yuan, reflecting a year-on-year increase of 21.02% [2]. - The company has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yingke Medical's stock price decreased by 2.01%, closing at 37.00 yuan per share, with a trading volume of 468 million yuan and a turnover rate of 2.67%. The total market capitalization is 24.227 billion yuan [1]. - Year-to-date, the stock price has increased by 46.94%, with a 3.99% rise over the last five trading days, a 1.73% decline over the last 20 days, and a 45.15% increase over the last 60 days [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders is 60,000, a decrease of 2.96% from the previous period. The average number of circulating shares per person is 7,825, an increase of 3.07% [2][3]. - The top circulating shareholders include Huabao Zhongzheng Medical ETF, E Fund Growth ETF, and Southern CSI 500 ETF, with varying changes in their holdings [3].

Core Viewpoint - The stock of Yingke Medical (300677) has shown a positive performance with a closing price of 37.05 yuan, reflecting a 1.51% increase on September 16, 2025, amidst varying capital flows from different investor groups [1][2]. Financial Performance - Yingke Medical reported a main revenue of 4.913 billion yuan for the first half of 2025, representing an 8.9% year-on-year increase [3]. - The net profit attributable to shareholders was 710 million yuan, up 21.02% year-on-year [3]. - The company's second-quarter revenue was 2.42 billion yuan, a 4.79% increase year-on-year, while the net profit for the same period was 358 million yuan, reflecting a 2.55% increase year-on-year [3]. - The company's gross profit margin stood at 24.23%, with a net profit margin of 14.79% [3]. Market Position - Yingke Medical's total market capitalization is 24.26 billion yuan, ranking 8th in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 17.07, significantly lower than the industry average of 69.34, indicating a potentially undervalued stock [3]. - The return on equity (ROE) is 4.03%, which is higher than the industry average of 1.8% [3]. Capital Flow Analysis - On September 16, 2025, the net inflow of main funds was 16.699 million yuan, accounting for 2.9% of the total transaction volume [1][2]. - Retail investors experienced a net outflow of 48.3817 million yuan, representing 8.39% of the total transaction volume [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with significant net outflows from retail investors on multiple days [2]. Institutional Ratings - In the last 90 days, six institutions have given a buy rating for Yingke Medical, with an average target price of 33.24 yuan [4].

Core Viewpoint - The stock of Yingke Medical (300677) has shown a recent increase in price and trading activity, with significant fluctuations in capital flow among different investor categories [1][2]. Group 1: Stock Performance - As of September 5, 2025, Yingke Medical's stock closed at 34.76 yuan, up by 2.24% with a trading volume of 146,000 hands and a total transaction value of 505 million yuan [1]. - Over the past five days, the stock experienced a high of 36.46 yuan and a low of 34.00 yuan, with a notable drop of 5.45% on September 4, 2025 [2]. Group 2: Capital Flow Analysis - On September 5, 2025, the net outflow of main funds was 5.45 million yuan, accounting for 1.08% of the total transaction value, while retail investors saw a net inflow of 18.87 million yuan, representing 3.73% of the total [1][2]. - The capital flow data indicates that retail investors have been more active in purchasing the stock, contrasting with the outflows from institutional and speculative funds [2]. Group 3: Financial Metrics and Industry Comparison - Yingke Medical's total market capitalization is 22.761 billion yuan, with a net asset value of 18.309 billion yuan and a net profit of 710 million yuan, ranking 10th, 4th, and 6th respectively in the medical device industry [3]. - The company's revenue for the first half of 2025 was 4.913 billion yuan, an increase of 8.9% year-on-year, while the net profit rose by 21.02% to 710 million yuan [3]. - The gross profit margin stands at 24.23%, significantly lower than the industry average of 51.85%, indicating potential areas for improvement [3]. Group 4: Analyst Ratings - In the last 90 days, five institutions have rated Yingke Medical with a "buy" recommendation, and the average target price set by these institutions is 38.86 yuan [4].

Core Viewpoint - The stock of Yingke Medical (300677) has shown a slight decline, with a closing price of 37.03 yuan on August 20, 2025, reflecting a decrease of 0.11% [1] Group 1: Stock Performance and Trading Data - On August 20, 2025, the stock experienced a turnover rate of 3.24%, with a trading volume of 150,800 hands and a total transaction value of 554 million yuan [1] - The net outflow of main funds was 22.35 million yuan, accounting for 4.03% of the total transaction value, while retail investors saw a net inflow of 50.99 million yuan, representing 9.2% of the total transaction value [1][2] Group 2: Recent Fund Flow Overview - Over the past five days, the stock has seen varying fund flows, with significant net inflows from retail investors on August 20, 2025, contrasting with net outflows from both main and speculative funds [2] - The stock's closing prices and changes over the last five days indicate a general downward trend, with the most significant drop occurring on August 19, 2025, at -1.70% [2] Group 3: Company Financial Metrics and Industry Comparison - Yingke Medical has a total market value of 24.247 billion yuan, with a net asset value of 18.042 billion yuan, and a net profit of 353 million yuan, ranking 9th, 4th, and 7th respectively in the medical device industry [3] - The company reported a gross margin of 24.16% and a net profit margin of 14.49%, with a return on equity (ROE) of 2.17%, indicating a competitive position in the industry [3] - For Q1 2025, the company achieved a main revenue of 2.494 billion yuan, reflecting a year-on-year increase of 13.2%, and a net profit growth of 48.08% [3] Group 4: Analyst Ratings and Target Price - In the last 90 days, four institutions have rated Yingke Medical with a "buy" recommendation, and the average target price set by these institutions is 33.24 yuan [4]

Core Viewpoint - The stock of Yingke Medical (300677) has shown a significant increase, closing at 37.28 yuan on August 1, 2025, with an 8.53% rise, indicating positive market sentiment and potential investment interest [1]. Financial Performance - For Q1 2025, Yingke Medical reported a main business revenue of 2.494 billion yuan, a year-on-year increase of 13.2% - The net profit attributable to shareholders was 353 million yuan, up 48.08% year-on-year - The net profit after deducting non-recurring gains and losses was 247 million yuan, reflecting a 53.22% increase year-on-year - The company's debt ratio stands at 51.61%, with investment income of 24.27 million yuan and financial expenses of -12.18 million yuan - The gross profit margin is reported at 24.16% [5][6]. Market Activity - On August 1, 2025, the net inflow of main funds was 14.73 million yuan, accounting for 0.9% of the total transaction volume - Retail investors experienced a net outflow of 77.28 million yuan, representing 4.7% of the total transaction volume - The stock's trading volume was 447,500 hands, with a total transaction amount of 1.643 billion yuan [1][2]. Financing and Margin Trading - On August 1, 2025, the financing buy-in was 168 million yuan, while financing repayment was 164 million yuan, resulting in a net financing buy-in of 4.58 million yuan - The margin trading balance stood at 712 million yuan, with a short selling of 20,700 shares and a remaining short position of 238,300 shares [2][3]. Industry Comparison - Yingke Medical's total market capitalization is 24.406 billion yuan, significantly higher than the industry average of 11.474 billion yuan, ranking 8th out of 122 in the medical device industry - The company's net assets are 18.042 billion yuan, ranking 4th in the industry - The price-to-earnings ratio (P/E) is 17.3, which is lower than the industry average of 61.54, ranking 9th in the industry - The gross profit margin of 24.16% is below the industry average of 51.09%, ranking 112th [5][6].